Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Claritev Corp. (CTEV)
NYSEHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-04
$20.22-6.69%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CTEV yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Free cash flow turns positive up to $10 million | The company plans positive free cash flow up to $10 million in 2026. | Intact | Free cash flow remains negative for full FY26 | Free cash flow: $54.591M FY2026-Q2; GAAP. Published target: >= $0 million and up to $10 million. Annual target cannot be compared with a quarterly or TTM observation. Aug 7, 202654,591,000 USD · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
CTEV is an execution-focused growth business, with recent results showing strong financial performance despite a loss-making earnings profile. Its long-term thesis is intact, but the evidence is mixed on AI delivery and near-term earnings remain hard to predict.
The valuation evidence is mixed: CTEV is described as cheap versus peers, while a separate measure shows a 19% peer premium. The model has low confidence, and the priced-in tag is justified, with no fragility flags; the evidence does not point to a clear expectations gap.
Near term, revenue growth and higher operating income support the business setup, and management has raised its free cash flow guidance range. Expanding into new markets and improving operations are on track, while AI-related results are not yet clearly measured. Recent earnings have been erratic, so a guidance cut remains a material near-term risk.
Over the next few quarters, the thesis depends on CTEV sustaining revenue growth, converting that growth into stronger operating results, and avoiding a guidance cut. A weakening jobs trend could weigh on cyclical healthcare names, while continued strong results from sector peers could support sector momentum.
For a 1 to 3 year view, the business has improving results and an intact thesis, but loss-making earnings and uneven surprises leave meaningful execution risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 2 supplied quarters. Management reported: “• Adjusted EBITDA of $155.8 million for Q2 2026, an increase of 1.1%, compared to Adjusted EBITDA of $154.0 million for Q2 2025.” “• Free Cash Flow of $54.6 million for Q2 2026, compared to Free Cash Flow of $36.6 million for Q2 2025.”
Operating income improves to positive territory | Operating income rose from a loss of $7.6 million to a gain of $6.6 million. | Intact | Operating income falls below $0 in any quarter next year | Operating income: $23.409M FY2026-Q2; GAAP. Published target: >= $6.6 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 7, 202623,409,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “• Adjusted EBITDA of $155.8 million for Q2 2026, an increase of 1.1%, compared to Adjusted EBITDA of $154.0 million for Q2 2025.” “• Free Cash Flow of $54.6 million for Q2 2026, compared to Free Cash Flow of $36.6 million for Q2 2025.” Delivery assessment Nov 4, 2026 |
Quarterly revenue remains near $240 million | Revenue stayed steady near $240 million per quarter. | Intact | Quarterly revenue falls below $230 million next year | Revenue: $257.478M FY2026-Q2; GAAP. Published target: >= $240 million per quarter. Target period is not explicitly aligned with this observation. Aug 7, 2026257,478,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$6.84 → $-13.53 · observed estimates
$1.04B → $1.06B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $6.84 | $1,038,203,520 | 1 / 4 |
| 2026-07-25 | $6.84 | $1,038,203,520 | 1 / 4 |
| 2026-07-26 | $6.84 | $1,038,203,520 | 1 / 4 |
| 2026-07-27 | $6.84 | $1,038,203,520 | 1 / 4 |
| 2026-07-28 | $6.84 | $1,038,203,520 | 1 / 4 |
| 2026-07-29 | $-13.87 | $1,038,203,473 | 2 / 3 |
| 2026-07-30 | $-13.87 | $1,038,203,473 | 2 / 3 |
| 2026-07-31 | $6.84 | $1,038,203,520 | 1 / 4 |
| 2026-08-01 | $-13.87 | $1,038,203,473 | 2 / 3 |
| 2026-08-02 | $6.84 | $1,038,203,520 | 1 / 4 |
| 2026-08-03 | $6.84 | $1,038,203,520 | 1 / 4 |
| 2026-08-04 | $-13.87 | $1,038,203,473 | 2 / 3 |
| 2026-08-05 | $6.84 | $1,038,203,520 | 1 / 4 |
| 2026-08-06 | $6.84 | $1,038,203,520 | 1 / 4 |
| 2026-08-07 | $-13.87 | $1,038,203,473 | 2 / 3 |
| 2026-08-08 | $6.84 | $1,038,203,520 | 1 / 4 |
| 2026-08-09 | $6.84 | $1,038,203,520 | 1 / 4 |
| 2026-08-10 | $6.84 | $1,038,203,520 | 1 / 4 |
| 2026-08-11 | $7.33 | $1,054,140,010 | 1 / 4 |
| 2026-08-12 | $-13.87 | $1,038,203,473 | 2 / 3 |
| 2026-08-13 | $7.33 | $1,054,140,010 | 1 / 4 |
| 2026-08-14 | $-13.87 | $1,038,203,473 | 2 / 3 |
| 2026-08-15 | $-13.87 | $1,038,203,473 | 2 / 3 |
| 2026-08-16 | $-13.87 | $1,038,203,473 | 2 / 3 |
| 2026-08-17 | $-13.87 | $1,038,203,473 | 2 / 3 |
| 2026-08-18 | $-13.87 | $1,038,203,473 | 2 / 3 |
| 2026-08-19 | $-13.87 | $1,038,203,473 | 2 / 3 |
| 2026-08-20 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-08-21 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-08-22 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-08-23 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-08-24 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-08-25 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-08-26 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-08-27 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-08-28 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-08-29 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-08-30 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-08-31 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-01 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-02 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-03 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-04 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-05 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-06 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-07 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-08 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-09 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-10 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-11 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-12 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-13 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-14 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-15 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-16 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-17 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-18 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-19 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-20 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-21 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-22 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-23 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-24 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-25 | $-13.53 | $1,068,181,658 | 2 / 3 |
| 2026-09-26 | $-13.53 | $1,068,181,658 | 1 / 2 |
| 2026-09-27 | $-13.53 | $1,068,181,658 | 1 / 2 |
| 2026-09-28 | $-13.53 | $1,068,181,658 | 1 / 2 |
| 2026-09-29 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-09-30 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-01 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-02 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-03 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-04 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-05 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-06 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-07 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-08 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-09 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-10 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-11 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-12 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-13 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-14 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-15 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-16 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-17 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-18 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-19 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-20 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-21 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-22 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-23 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-24 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-25 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-26 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-27 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-28 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-29 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-30 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-10-31 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-11-01 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-11-02 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-11-03 | $-13.53 | $1,062,903,700 | 1 / 2 |
| 2026-11-04 | $-13.53 | $1,062,903,700 | 1 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.